| 15.37 -0.09 (-0.58%) | 09-17 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 18.38 | 1-year : | 19.02 |
| Resists | First : | 15.73 | Second : | 16.29 |
| Pivot price | 15.53 |
|||
| Supports | First : | 14.85 | Second : | 12.35 |
| MAs | MA(5) : | 15.45  |
MA(20) : | 15.59 |
| MA(100) : | 13.4 |
MA(250) : | 12.22 |
|
| MACD | MACD : | 0 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 45.3 |
D(3) : | 46 |
| RSI | RSI(14): 49.8 |
|||
| 52-week | High : | 16.29 | Low : | 9.39 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ANGO ] has closed above bottom band by 35.0%. Bollinger Bands are 32.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 15.63 - 15.72 | 15.72 - 15.79 |
| Low: | 15.11 - 15.22 | 15.22 - 15.31 |
| Close: | 15.21 - 15.37 | 15.37 - 15.51 |
AngioDynamics, Inc. specializes in the development, manufacturing, and commercialization of a diverse array of medical, surgical, and diagnostic instruments. These products are utilized by healthcare professionals to address conditions such as peripheral vascular disease, facilitate vascular access, and support various oncology and surgical interventions, serving both domestic and international markets. The company's portfolio includes advanced ablation systems like NanoKnife, designed for the precise surgical removal of soft tissues, and Solero microwave and radiofrequency systems, effective in ablating solid cancerous or benign growths. Additionally, they provide BioSentry tract sealant systems, IsoLoc Endorectal Balloons, Alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. Their endovascular therapies segment encompasses solutions for thrombus management, atherectomy procedures, core peripheral products, and the treatment of venous insufficiency. Furthermore, AngioDynamics is a key supplier of vascular access devices, such as peripherally inserted central catheters (PICCs), midline catheters, implantable ports, and dialysis catheters, along with associated accessories. These are primarily employed for short-duration systemic drug delivery, including chemotherapy and antibiotics, marketed under a robust portfolio of brand names such as BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax. The company distributes its offerings directly to a specialized clientele, including interventional radiologists, cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses, while also leveraging established distributor networks. Founded in 1988, AngioDynamics maintains its corporate headquarters in Latham, New York.
Wed, 09 Sep 2026
How Angiodynamics Inc. (ANGO) Affects Rotational Strategy Timing - Stock Traders Daily
Tue, 11 Aug 2026
AngioDynamics, Inc. (ANGO) Presents at Canaccord Genuity's 46th Annual Growth Conference - Slideshow - Seeking Alpha
Fri, 31 Jul 2026
AngioDynamics (ANGO) SVP Warren Nighan Jr. sells 23,370 shares at $14.72 - Stock Titan
Sat, 25 Jul 2026
AngioDynamics, Inc. Revenue Breakdown – NASDAQ:ANGO - TradingView
Tue, 14 Jul 2026
AngioDynamics (ANGO) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Tue, 30 Jun 2026
AngioDynamics sets July 14 call for fiscal 2026 results - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 41 (M) |
| Shares Float | 32 (M) |
| Held by Insiders | 12.6 (%) |
| Held by Institutions | 94 (%) |
| Shares Short | 1,350 (K) |
| Shares Short P.Month | 1,320 (K) |
| EPS | -0.88 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.09 |
| Profit Margin | -11.5 % |
| Operating Margin | -6.6 % |
| Return on Assets (ttm) | -5.2 % |
| Return on Equity (ttm) | -20.8 % |
| Qtrly Rev. Growth | 8 % |
| Gross Profit (p.s.) | 4.23 |
| Sales Per Share | 7.74 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 3 (M) |
| Levered Free Cash Flow | 22 (M) |
| PE Ratio | -17.47 |
| PEG Ratio | 1.4 |
| Price to Book value | 3.74 |
| Price to Sales | 1.98 |
| Price to Cash Flow | 205.57 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|